Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TIPPS: Zonisamide neuroprotective effects in early Parkinson's disease using PET
jRCTs041180070Active, not recruiting
- Sponsor
- Sumitomo Pharma
- Start
- Nov 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of zonisamide in Parkinson's disease (PD) (2 arms), sponsored by Sumitomo Pharma. Primary endpoints: Binding potential of 11C-CFT (dopamine transporter) and Binding potential of 11C-DPA713 (TSPO in activated microglia). Started Nov 2015; status: active, not recruiting.
02
Drugs
zonisamide
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on jRCTs041180070.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs041180070.